Our clueless, pseudo-intellectual narcissist of a president (notice deliberate lower case use) has targeted the financial services industry. Until this clown is gone, banks, brokers, money managers etc will not reach potential.
With 7.5% div at current price, 22 is not likely. If it does come, buy with both hands. Today it traded down the amount of the dividend (today was X date) and considering the Dow was down 300+, that is pretty impressive.
Yellen announced initiating coverage on the biotech industry today with a "sell" recommendation. It knocked hell out of the stocks, includings ALKS. Thanks Janet, it is a lovely buying opportunity.
Nah, news of deals always leaks. the stock would be way up on Thursday if a deal was coming. Besides, who closes a deal on July 4th weekend.
The frauds posting on this board are those who regularly reported the Brother were selling, despite the lack of Form 4's being filed. The only reason they are not facing an SEC investigation is that the staff doesn't believe these boards matter. Too bad.
Nah, we bulls saw the pop and got in and out before it fell. Your money is in my pocket. As for the core holdings, I will still have those five years from now unless we are bought out. This company is a leader in this industry, and taking the time to build its foundation is great management.
I have never understood the animosity of Zacks to this stock. When the stock price was climbing for years, Zacks was a "hold" and bad mouthed the one trick pony. Now there is a pipeline and multiple products, and Zacks is in its glory. They could be made fools of in a single day with a buyout, and in any case are a year away from being very wrong again. If you are a talented analyst, why would you work for Zack? That is where you go when you don't make it at a Street firm.
Interesting. Wall Street Journal publishes favorable story about prostate treatment and the stock has been up a couple of days. If I were an SEC examiner, I would be looking for evidence of early knowledge of the publication to come. Let's see the next Form 4's to see who are the really smart guys.
End of the line for the lead bullet? Regulations, bans force switch to 'green' ammo
By Perry Chiaramonte/
This can only do wonders for copper demand:
The Army's new round replaces the current M855 5.56mm cartridge that has been used by U.S. troops since the early 1980s. The Army claims the M855A1 is more dependable, a more consistent performer, improves accuracy, moves faster. (U.S. Army)
When the last bullet-producing lead smelter closes its doors on Dec. 31, it will mark a major victory for those who say lead-based ammunition pollutes the environment, but others warn 'green' bullets will cost more, drive up copper prices and do little to help conservation.
The bid to ban lead bullets, seen by some as harmful to the environment, started slowly more than a decade ago. But with two dozen states, including California, banning bullets made of the soft, heavy metal, the lead bullet's epitaph was already being written when the federal government finished it off.
First, the military announced plans to phase out lead bullets by 2018.
"Whatever the EPA's motivation when creating the new lead air quality standard, increasingly restrictive regulation of lead is likely to affect the production and cost of traditional ammunition."
Then the federal Environmental Protection Agency, citing emissions, ordered the shutdown of the Doe Run company's lead smelter in Herculaneum, Mo., by year's end.
Whether by state or federal regulation, or by market forces, lead bullets will be all but phased out within a few years in favor of so-called green bullets, experts say. While many believe that this will help the environment by keeping lead from contaminating groundwater, others say switching to copper-based bullets will cost hunters and sportsmen more and have little effect on the environment.
Genomic Health Announces Third Quarter 2013 Financial Results and Business Progress
Product Revenue Increased 13% Compared to Prior Year
NICE Recommends Oncotype DX® as Only Breast Cancer Test to Predict Chemotherapy Benefit
Conference Call Today at 4:30 p.m. ET
REDWOOD CITY, Calif., Nov. 5, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended September 30, 2013.
Product revenue was $65.7 million in the third quarter of 2013, compared with $58.4 million for the third quarter of 2012, an increase of 13 percent. Total revenue for the third quarter of 2013 increased to $66.0 million, compared with $58.6 million in the third quarter of 2012.
International product revenue grew by 25 percent to $10.1 million compared to the same period in 2012, and represented 15 percent of product revenue in the third quarter of 2013.
Net income in the third quarter of 2013 was $0.5 million, compared with net income of $3.7 million in the third quarter of 2012. Basic and diluted net income per share applicable to common stockholders was $0.02 for the third quarter of 2013, compared with a basic and diluted net income per share of $0.12 and $0.11, respectively for the same period in 2012.
"Our strong third quarter performance, including 13 percent year-over-year growth in product revenue, was driven by double digit test volume growth in all areas of our business," said Kim Popovits, Chairman of the Board, Chief Executive Officer and President of Genomic Health. "Success in the quarter was also highlighted by increased adoption of our prostate cancer test and NICE's recommendation of Oncotype DX as the only test to help clinicians decide whether to prescribe chemotherapy in patients with early-stage, hormone receptor-positive, invasive breast cancer."
Additional Third Quarter 2013 and Nine Months Ended September 30, 2013 Results
Total operating expenses for the third quarter of 2013 were $65.5 million, compared with total operating expenses of $54.9 million for the comparable period in 2012.
Product revenue for the nine months ended September 30, 2013 was $192.1 million, compared with $173.5 million for the nine months ended September 30, 2012, an increase of 11 percent. Total revenue for the nine months ended September 30, 2013 was $192.8 million, compared with $174.7 million for the same period in 2012.
Net loss was $3.4 million for the nine months ended September 30, 2013, compared with net income of $6.3 million for the nine months ended September 30, 2012.
Cash and cash equivalents and short-term investments at September 30, 2013 were $114.0 million, compared with $99.1 million at December 31, 2012.
In the third quarter, more than 21,790 Oncotype DX test results were delivered, an increase of 21 percent, compared with more than 18,030 test results delivered in the same period in 2012.
You write like a teenager, you obviously have no real training in finance, and if FINRA actually enforced suitability requirements you would not be allowed to trade. As it is, your losses provide the liquity that makes the markets work, so at the end of the day, it is worthwhile letting you in. Why don't you give us an example, moron, of a "manipulation, assuming you can stop masturbating long enough to wash your hands and hit the keyboard.